{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-001149","form_type":"8-K","ticker":"KNSA","cik":"0001730430","company_name":"Kiniksa Pharmaceuticals International, plc","filed_at":"2024-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.289578+00:00","generated_at":"2026-06-07T04:06:44.055536+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kiniksa reports ARCALYST 2023 net revenue $233.1M; abiprubart Phase 2 meets primary endpoint","bullets":["ARCALYST 2023 net product revenue $233.1M, up ~90% YoY; Q4 2023 revenue $71.2M.","2024 ARCALYST net product revenue guidance set at $360M-$380M.","Abiprubart Phase 2 RA trial met primary endpoint at 5 mg/kg weekly dose (p=0.0487); 5 mg/kg biweekly missed.","Cash, equivalents, and short-term investments $206.3M expected to fund operations into at least 2027.","~9% of target 14,000 multiple-recurrence pericarditis patients on ARCALYST; salesforce expanded to ~85 reps."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-001149","json":"https://secwatch.observer/filing/0001104659-24-001149.json","markdown":"https://secwatch.observer/filing/0001104659-24-001149.md","text":"https://secwatch.observer/filing/0001104659-24-001149.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/0001104659-24-001149-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/tm241815d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T04:06:44.055536+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5d0f8447e052e0f376e6f3a2de5c7aae3bcef6e","claim":"Kiniksa Pharmaceuticals International, plc reported the fourth quarter and full year 2023 results: revenue ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud. Guidance initiated.","evidence_excerpt":"On January 4, 2024, Kiniksa Pharmaceuticals, Ltd. (the “Company”) issued a press release (the “Press Release”) announcing, among other things, that (i) its preliminary year-end 2023 cash, cash equivalents and short-term investments of $206.3 million (unaudited) are expected to fund its current operating plan into at least 2027 and (ii) ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaudited).","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1730430/000110465924001149/0001104659-24-001149-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year 2023"},{"label":"Revenue","value":"ARCALYST net revenue was $71.2 million and $233.1 million for the fourth quarter and full year 2023, respectively (unaud"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}